GlycoMimetics Inc

NASDAQ:GLYCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).

Contact Information

Headquarters

9708 Medical Center DriveROCKVILLE, MD, United States 20850

Phone

240-243-1201

Fax

240-243-1018

Executives

Independent Chairman of the Board

Timothy Pearson

President, Chief Executive Officer, Director

Harout Semerjian

Co-Founder, Director

Rachel King

Chief Financial Officer, Senior Vice President

Brian Hahn

Senior Vice President, Chief Commercial Officer

Bruce Johnson